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Purpose: To assess the in vitro effects of simvastatin on IL-10 and TNF-a secretion from peripheral blood
mononuclear cells (PBMC) of critically ill patients with and without acute kidney injury (AKI).
Methods: PBMC were collected from 63 patients admitted to the intensive care unit (ICU) and from 20
healthy controls. Patients were divided in 3 subgroups: with AKI, with sepsis and without AKI and with
AKI and sepsis. After isolation by ﬁcoll-gradient centrifugation cells were incubated in vitro with LPS
1 ng/mL, simvastatin (108M) and with LPS plus simvastatin for 24 h. TNF-a and IL-10 concentrations on
cells surnatant were determined by ELISA.
Results: Cells isolated from critically ill patients showed a decreased spontaneous production of TNF-a and
IL-10 compared to healthy controls (6.7 (0.2–12) vs 103 (64–257) pg/mL and (20 (13–58) vs 315 (105–510)
pg/mL, respectively,p < 0.05). Under LPS-stimulus, IL-10production remains lower in patients compared to
healthy control (451 (176–850) vs1150 (874–1521) pg/mL,p < 0.05) but TNF-aproductionwas higher (641
(609–841) vs 406 (201–841) pg/mL, p < 0.05). The simultaneous incubation with LPS and simvastatin
caused decreased IL-10 production in cells from patients compared to control (337 (135–626) vs 540
(345–871) pg/mL, p < 0.05) and increased TNF-a release (711 (619–832) vs 324 (155–355) pg/mL,
p < 0.05). Comparison between subgroups showed that the results observed in TNF-a and IL-10 production
by PBMC from critically ill patients was independent of AKI occurrence.
Conclusions: The PBMC treatment with simvastatin resulted in attenuation on pro-inﬂammatory cytokine
spontaneous production that was no longer observed when these cells were submitted to a second inﬂam-
matory stimulus. Our study shows an imbalance between pro and anti-inﬂammatory cytokine production
in PBMC from critically ill patients regardless the presence of AKI.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The systemic inﬂammatory response (SIRS) to severe infection
remains the leading cause of death among critically ill patients
[1]. Despite extensive research, over more than two decades, the
mortality rates may reach more than 70% [2–4]. This inﬂammatory
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sevier OA license.cytokines, such as TNF-a, IL-6, IL-8 and the activation of plasma
protein cascade systems. Although numerous studies have at-
tempted to develop therapeutic approaches on the ﬁeld, no effec-
tive improvement on patient’s outcome have been achieved.
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors (statins) have antihypercholesterolemic ef-
fects by catalyzing the formation of mevalonate from acetyl-CoA,
resulting in positive effects on lipid proﬁle [5,6]. Recent studies
have demonstrated that statins have several nonlipid properties
called pleiotropic effects. These pleiotropic effects include
anti-inﬂammatory actions, modulation of endothelial nitric oxide
synthase (eNOS) resulting in improvement of endothelial and
microvascular function [7]. These effects might account for the
observed beneﬁts of statins in patients with any inﬂammatory dis-
order [8,9]. A report of Ando et al. suggested that pretreatment
Fig. 1. Dose–response effect os simvastatin on PBMC’s cytokines release.
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The translation of such ﬁndings to clinical settings shows that sta-
tin therapy may reduce mortality in patients with bacteremia [11].
In addition, in vitro and in vivo studies have demonstrated that
simvastatin has anti-inﬂammatory effect in patients with pre-dia-
lytic chronic kidney disease, and may play an important role in
counteracting the mechanisms involved in pathogenesis of inﬂam-
mation [12].
Acute kidney injury (AKI) is a frequent complication in critically
ill patients and has been associated with an excess risk of hospital
mortality that ranges rates of 50–80% [13]. There are evidences
showing the involvement of intrarenal inﬂammation in ische-
mia–reperfusion injury using in vitro and in vivo models, which
makes this scenario an interesting target for the development of
new strategies for AKI management [14]. Although some evidences
suggested that statins reduce morbidity related to SIRS, the effects
of statin treatment in critically ill patients with AKI have not been
properly explored so far. Therefore, this study was conducted to as-
sess the in vitro effects of simvastatin on IL-10 and TNF-a secretion
from peripheral blood mononuclear cells (PBMC) of critically ill pa-
tients with and without AKI.
2. Materials and methods
In this study we evaluated the secretion of IL-10 and TNF-a by
cultured human peripheral mononuclear blood cell’s (PBMC’s) iso-
lated from healthy subjects and critically ill patients.
2.1. Patients and healthy volunteers
The study population consisted of 63 patients admitted to the
intensive care unit (ICU) of Hospital Israelita Albert Einstein, São
Paulo, Brazil. Acute Physiology and Chronic Healthy Evaluation II
(APACHE II) was routinely used as severity of disease score [15].
All patients were enrolled into this study under informed consent
guidelines approved by the Investigation Review Boards of the Fed-
eral University of São Paulo and Albert Einstein Hospital. The con-
trol group (n = 20) included healthy adult volunteers. Patients who
were <18 years of age were not included. Baseline demographic
and clinical data were obtained from the patients hospital records.
For further analysis, critically ill patients were sub-divided on
those who developed AKI (N = 20), a group who developed sepsis
without AKI (N = 22) and a third group who had sepsis with AKI
(N = 21). Patients with AKI were deﬁned by the Acute Kidney Injury
Network (AKIN) criteria. The diagnostic criteria for acute kidney in-
jury is deﬁned by an abrupt (within 48 h) reduction in kidney func-
tion, currently deﬁned as an absolute increase in serum creatinine
of more than or equal to 0.3 mg/dl (P26.4 lmol/l), a percentage in-
crease in serum creatinine of more than or equal to 50% (1.5-fold
from baseline), or a reduction in urine output (documented oligu-
ria of less than 0.5 ml/kg per hour for more than 6 h) [16].
Patients with SIRS were deﬁned by the occurrence of at least
two of the following criteria: (a) a temperature of >38 or < 36 C;
(b) an increased heart rate of >90 beats/min; (c) tachypnea, and
(d) altered white blood cells count of >12,000,<4000 cells/mm3,
or the presence of >10% immature neutrophils [1]. Patients with
sepsis were stratiﬁed by the same clinical response described
above plus the occurrence of an infectious focus [1].
The exclusion criteria included patients with end-stage renal
disease, renal transplanted patients, and previous participation in
this study.
2.2. Blood sampling
Forty mL of peripheral blood was collected from patients in the
ﬁrst 48 h of ICU admittance and healthy volunteer’s samples wascollected as well in sterile heparinized syringes and immediately
transferred to the laboratory for cell isolation procedure.
2.3. Biochemical methods
Renal function was evaluated by serum urea, creatinine, sodium
and potassium using standard auto-analyzer techniques [17–20].
The C-reactive protein (CRP) was measured by immune turbi-
dimetry technique [21] and leukocytes were automatically
counted at CELL DYN 3200 (ABBOTT).
2.4. Cell isolation procedure
For isolation of mononuclear cells, 40 mL of blood were col-
lected and PBMC’s were isolated by Ficoll-gradient centrifugation
(Histopaque-1077, Sigma–Aldrich Co.) from blood that was with-
drawn into tubes containing heparin as coagulant. Cells were
washed in NaCl 0.9% solution, counted and cultured in RPMI
1640 medium (Sigma–Aldrich Co.) supplemented with 50% of fetal
bovine serum and antibiotics in 6-well plates at 37 C in an atmo-
sphere containing 5% CO2. Cell viability was assessed by Trypan
Blue method.
The cells were incubated with lipopolysaccharide (LPS) from
Escherichia coli (Sigma–Aldrich Co.) at a ﬁnal concentration of
1 ng/ml and simvastatin (Sigma–Aldrich Co.) for 24 h. The PBMC
were incubated in the following conditions: only RPMI 1640 med-
ium, medium with LPS, medium with simvastatin 108 M and
medium with LPS and simvastatin 108 M simultaneously.
2.5. Dose effects of simvastatin on cytokines release by PBMC
To determine optimal simvastatin concentration on cytokines
release by PBMC, cells isolated from healthy subjects (N = 5) as de-
scribed above, were incubated with increasing doses of simvastatin
(1010, 108 and 106 M) for 24 h. Previously, simvastatin was di-
luted and activated as followed: in a 1.5-mL tube, 5 mg sinvastatin
(Sigma) were dissolved in 190 lL DMSO and 810 lL Milli-Q water.
NaOH, 0.1 M, was added to the tube, which was then heated at
70 C for 2 h (activation protocol) [12]. This solution was serially
diluted with DMEN medium, in order to obtain a medium with
1010, 108 and 106 M simvastatin. The PBMCs were incubated
in the following conditions: only RPMI 1640 medium and medium
with increasing concentrations of simvastatin (1010, 108 and
106 M). Concentrations of TNF-a and IL-10 were determined in
the 24 h culture supernatants of PBMCs. In this preliminary exper-
imental protocol, our data indicates that simvastatin had no dose-
dependent effect (Fig. 1) and, therefore, 108 M concentration was
chosen to carry out the study. Under LPS stimulating condition
simvastatin either had no dose-dependent effect (data not shown).
Table 1
Baseline characteristics of healthy controls and critically ill patients stratiﬁed by the occurrence of acute kidney injury (AKI), sepsis, and AKI related to sepsis.
Healthy controls (N = 20) AKI (N = 20) Sepsis (N = 22) AKI + sepsis (N = 21) Total of patients (N = 63) p
Male sex (%) 65 55 50 71 67 NS
Age (years) 64 ± 14 64 ± 16 65 ± 20 63 ± 18 64 ± 17 NS
Creatinine (mg/dL) # 2.0 ± 1.5 1.0 ± 1.1 2.3 ± 1.6* 1.7 ± 1.5 0.05
Urea (mg/dL) # 59 ± 31 46 ± 26 90 ± 50* 65 ± 41 0.017
Sodium (mg/dL) # 137 ± 5 137 ± 3 137 ± 5 137 ± 5 NS
Potassium (mg/dL) # 4.6 ± 0.7 4.4 ± 0.4 4.5 ± 0.6 4.5 ± 0.6 NS
CRP (mg/dL) # 7.0 ± 5.4 7.9 ± 9.8 7.5 ± 5.7 7.6 ± 7.6 NS
Total leukocyte count # 10,500 ± 5627 8327 ± 3863 13,298 ± 9482* 10,674 ± 6932 0.055
APACHE score # 22 ± 10 19 ± 6 21 ± 7 21 ± 8 NS
Mortality (%) # 25 9 47* 27 0.017
NS: Not signiﬁcant.
# Data not evaluated.
* p < 0.05, AKI + sepsis vs sepsis.
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cells isolated from critically ill patients raised maximum produc-
tion of TNF-a after 24 h of incubation with LPS; all assays were car-
ried out during this period (data not shown).
2.6. Measurement of TNF-a and IL-10
Concentrations of TNF-a and IL-10 were determined in the 24 h
culture supernatants of PBMCs using commercially available en-
zyme linked immunosorbent assay (ELISA) kits (BD OptEIA). The
results were normalized to the PBMC concentration of 1  106 cells
and expressed in mg/dL. All analysis was performed according to
the manufacturer’s protocols. Sensitivities for the TNF-a and
IL-10 ELISAs were 2 pg/mL. The average intra assay coefﬁcient of
variation for TNF-a and IL-10 were 64.5% and 67.1% respectively.
TNF-a/IL-10 log ratio was expressed as surrogate of inﬂamma-
tory modulation.
2.7. Statistic analysis
Data were expressed as interquartile ranges (IQR) as appropri-
ate. Comparisons among groups were made with ANOVA plus Bon-
ferroni. To evaluate cytokine production into the group we
performed the one-way analysis of variance. X2 or Ficher’s exact
test were used for categorical variables. A subgroup analysis was
performed to compare critically ill patients stratiﬁed by the occur-
rence of AKI, sepsis and AKI related to sepsis. All the analysis was
performed using SPSS 16.0. p values of less than 0.05 were consid-
ered statistically signiﬁcant.
3. Results
The patients’ baseline characteristics and their laboratory
parameters are shown in Table 1. Patients with AKI related to sep-Table 2
Diagnosis at ICU admission of critically ill patients.
Diagnosis at ICU admission Total (n = 63)
Cardiovascular (%) 5 (7.9)
Respiratory (%) 1 (1.6)
Gastrointestinal/hepatic (%) 8 (12.7)
Metabolic (%) 1 (1.6)
Trauma (%) 1 (1.6)
Surgical (%) 4 (6.3)
Sepsis (%)
Respiratory sepsis 22 (34.9)
Abdominal sepsis 9 (14.3)
Sepsis 7 (11.1)
Gastrointestinal sepsis 3 (4.8)
Urinary sepsis 2 (3.2)sis had higher serum urea levels and total leukocyte counts com-
pared to septic subjects (p < 0.05). The control group, comprised
of healthy subjects, was not tested for the laboratory parameters
and presented amean age of 64 years and 65% ofmale sex (Table 1).
Diagnosis at admission in ICU is reported in Table 2.
The priming of PBMCs TNF-a production in critically ill patients
appears to be a speciﬁc effect since IL-10 production is not en-
hanced by LPS stimulation.
Compared to healthy controls, critically ill patients showed a
decreased spontaneous production of TNF-a and IL-10 (6.7 (0.2–
12) vs 103 (64–257) pg/mL and (20 (13–58) vs 315 (105–510)
pg/mL, respectively, p < 0.05) in PBMC. With LPS stimulation,
IL-10 production remained lower in patients compared to healthy
controls (451 (176–850) vs 1150 (874–1521) pg/mL, p < 0.05), but
TNF-a production was 1.3-fold higher compared to healthy control
(641 (609–841) vs 406 (201–841) pg/mL, p < 0.05).
Occurrence of AKI does not lead to differences in cytokine pro-
duction between subgroups of critically ill patients.
The comparison between subgroups showed that the results ob-
served in TNF-a and IL-10 production by PBMC from critically ill
patients was independent of occurrence of AKI (Fig. 2).
Simvastatin treatment reduces the TNF-a/IL-10 ratio in PBMC of
critically ill patients compared to healthy control (Table 3).
In simvastatin-treated PBMC isolated from critically ill patients,
the production of TNF-a and IL-10 remained lower than that of the
healthy control group (1.7 ± 1.3 vs 2.4 ± 0.2; and 1.4 ± 0.6 vs
2.1 ± 0.4 pg/mL, respectively, p < 0.05). The decrease in TNF-a/IL-
10 ratio observed with simvastatin treatment was consistent in
all subgroups (Fig. 2C).
Effect of simultaneous incubation of PBMC with LPS and 108 M
simvastatin on priming of PBMC and TNF-a production in critically
ill patients.
Taking the whole group of critically ill patients, it was observed
that simultaneous incubation with LPS and simvastatin caused a
decrease in IL-10 PBMC’s production compared to healthy control
cells (337 (135–626) vs 540 (345–871) pg/mL, p < 0.05) and in-
creased TNF-a (711 (619–832) vs 324 (155–355) pg/mL, p < 0.05).4. Discussion
In the present study we found a signiﬁcant reduction in sponta-
neous release of IL-10 and TNF-a by PBMC isolated from critically
ill patients compared to healthy control. These results suggest a
preactivation of cells from critically ill patients that resulted in a
decreased spontaneous IL-10 and TNF-a production. In fact, studies
have shown a down regulation of nuclear factor-kappa B (NF-jB)
in PBMC from sepsis patients, due to an imbalance between its ac-
tive (p65p50) and inactive (p50p50) forms and to a weak cytoplas-
mic expression of its inhibitor (IjBa) [22].
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Fig. 2. Comparison of TNF-a/IL-10 production ratio between group control and critically ill patients stratiﬁed in AKI, sepsis, and AKI related to sepsis.
Table 3
Comparison of TNF-a/IL-10 ratio between group control and critically ill patients.
TNF-a/IL-10 (IQR)
Control (N = 20) Critically ill patients (N = 63)
Spontaneous 0.6 (0.2–5.6) 0.16 (0.0001–0.7)
LPS 0.6 (0.4–0.8) 1.2 (0.2–7.1)*
S8 2.2 (0.9–3.9) 0.3 (0.001–0.5)*
S8 + LPS 1.5 (0.9–1.9) 2.4 (0.2–11.9)*
* p < 0.05, compared to control. Data are expressed as medians and interquartile
ranges (brackets).
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els but decreased monocyte IL-10 production in hemodialysis pa-
tients compared to healthy subjects [23]. In agreement with our
ﬁndings, these authors attributed the observed reduction in cyto-
kine secretion to monocyte preactivation. Moreover, decreased
IL-10 production in our patients was observed independent of
AKI occurrence, suggesting that this effect could be related to the
inﬂammatory response dysfunction of critically ill patients per se.
In fact, Van Deuren et al. demonstrated that patients with menin-
gococcal infection also have reduced levels of IL-8, IL-10, IL-12 and
INF-c [24].We observed upon exposure of cells to LPS, a high TNF-a pro-
duction associated with low IL-10 production, suggesting an unop-
posed pro-inﬂammatory state in critically ill patients. PBMCs from
critically ill patients seemed to be in a primed state. The occur-
rence of AKI did not reﬂect a different pattern in the secretion of
pro-inﬂammatory cytokines. It is well known that TNF-a plays an
important role in acute diseases. In the course of sepsis, there is
a biphasic inﬂammatory response characterized by an initial
hyperinﬂammatory phase changing to a hypoinﬂammatory state
[25]. This hyporeactivity was observed in monocytes/macrophages
after tolerance to endotoxin was induced in vivo and in vitro by LPS
it self [25]. Thus, the differences in magnitude of pro-inﬂammatory
cytokine production between TNF-a and IL-10, observed in our re-
sults, are likely to be inﬂuenced by the type and severity of disease,
as well as the mononuclear cell functionality.
Our study population consisted mainly of patients with SIRS
and sepsis. In this case, the exacerbation of pro-inﬂammatory re-
sponse with LPS exposure could be explained by the preactivation
state of PBMC isolated from critically ill patients. On the other
hand, our results showed a decreased anti-inﬂammatory response,
since with LPS stimulus IL-10 production remained reduced com-
pared to healthy subjects. In fact, Walley et al. suggested that the
balance between inﬂammatory mediators is related to severity
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sepsis was associated with higher anti-inﬂammatory mediator
expression [26].
IL-10 seems to play a pivotal position in the regulatory mecha-
nism that induces LPS desensitization, and it is essential for induc-
tion but not for maintenance of LPS hyporesponsiveness [25]. On
the other hand, TNF-a induces IL-10 synthesis and increases the
binding of this cytokine to polymorphonuclear leukocytes by
increasing the mobilization of IL-10 receptors from the intracellu-
lar granules to the cell membrane [27]. Taken together, our ﬁnd-
ings suggest that pro-inﬂammatory cytokine synthesis was not
able to modulate IL-10 production indicating that the acute inﬂam-
matory processes in critically ill patients could be associated with a
impairment in the signaling pathway of cytokine production in
SIRS.
In the present study, we also showed that treatment with sim-
vastatin led to a decrease in IL-10 and TNF-a production compared
with control, regardless of the presence of AKI. Moreover, the
simultaneous addition of LPS and simvastatin did not result in a
decrease in the inﬂammatory response of critically ill patients
compared to healthy subjects. Erikstrup et al., in studying 30 young
healthy males that received an injection of the bacterial cell wall
product endotoxin to induce systemic inﬂammation, demonstrated
that short-term treatment with simvastatin did not inﬂuence cir-
culating cytokine levels during endotoxemia [28]. In addition, in
a recent study of 295 blunt-injured adults with hemorrhagic shock,
Neal et al. demonstrated that the previous use of statins was re-
lated with higher in-hospital morbidity [29]. In this multicenter
prospective cohort study, preinjury statin use was independently
associated with the development of multiple organ failure syn-
dromes. Therefore, similar to what we showed with the additional
LPS stimulus, Neal et al. suggested that the protective effect of
HMG-CoA reductase inhibitor may be lost in the severe clinical set-
ting, and that exacerbation of the inﬂammatory response might
have been involved in their ﬁndings [29].
5. Conclusions
In conclusion, our study shows an imbalance between pro- and
anti-inﬂammatory cytokine productions in mononuclear cells from
critically ill patients, regardless of the presence of AKI. The treat-
ment of these cells with simvastatin resulted in attenuation of
spontaneous pro-inﬂammatory cytokine production which was
no longer observed when these cells were submitted to a second
inﬂammatory stimulus. Further studies are necessary to under-
stand the effects of statin use on the inﬂammatory response trig-
gered in the acute disease state.
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